Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade

Stock Information for Protara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Protara Therapeutics Inc.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics Announces Addition to the Russell 3000® Index
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.